Description

Technical Parameters

Introduction

peptides

product-1400-1400

Products Description

#### **Introduction**

Gonadotropin-releasing hormone (GnRH, also known as LHRH) is a decapeptide neurohormone secreted by the hypothalamus, which affects gonadal function by regulating the release of pituitary gonadotropins (FSH and LH). Based on its physiological effects, synthetic GnRH analogs (agonists and antagonists) are widely used in the treatment of hormone-dependent tumors (such as prostate cancer, breast cancer), endometriosis, precocious puberty and assisted reproductive technology. Triptorelin, as a representative drug of GnRH agonists, has become one of the core clinical drugs since the 1980s. This article will systematically analyze this type of compound from the aspects of classification, physicochemical properties, pharmacological characteristics and clinical application.

### **1. Classification of GnRH analogs**

Based on the different mechanisms of action and chemical modifications, GnRH analogs can be divided into the following two categories:

#### **1. GnRH Agonists**

**Mechanism of action**: By binding with high affinity to the pituitary GnRH receptor, it briefly stimulates the release of gonadotropin in the early stage ("ignition effect"), and then leads to long-term suppression of gonadal function due to receptor desensitization.

**Representative drugs**:

- **Triptorelin**: 2nd generation agonist with long half-life and sustained-release formulation.

- **Leuprorelin**: The first long-acting agonist, widely used for prostate cancer.

- **Goserelin**: Implantable formulation, suitable for breast cancer and endometriosis.

- **Buserelin**: Nasal spray formulation, used for assisted reproduction.

**Advantages**:

- Long-acting sustained-release preparations reduce the frequency of administration (1-6 months/time).

- Wide range of indications and clear efficacy.

- Mature production process and controllable cost.

**Disadvantages**:

- Symptoms may be aggravated in the initial stage (such as bone pain, elevated tumor markers).

- Anti-androgen drugs are required to offset the "ignition effect".

#### **2. GnRH antagonists**

**Mechanism of action**: Direct competitive blocking of GnRH receptors, rapid inhibition of gonadotropin secretion, no initial stimulation effect.

**Representative drugs**:

- **Degarelix**: The first approved long-acting antagonist for prostate cancer.

- **Cetrorelix**: Inhibition of premature LH peak in assisted reproduction.

- **Ganirelix**: Short-acting antagonist for IVF cycles.

**Advantages**:

- Rapid onset (suppresses testosterone within 24 hours), no "ignition effect".

- Suitable for emergency patients who need rapid hormone suppression.

**Disadvantages**:

- Short half-life, frequent dosing required (except Degarelix).

- Higher risk of allergic reactions (related to histamine release).

### **2. Physical and chemical properties and preparation characteristics**

#### **1. Chemical structure and stability**

- **Triptorelin**: The molecular formula is C₆₄H₈₂N₁₈O₁₃, with a molecular weight of 1311.5 Da. Its structure replaces the 6th glycine of natural GnRH with D-tryptophan and removes glycinamide at the 10th position, which significantly enhances receptor affinity and resistance to enzymatic hydrolysis.

- **Thermal stability**: The lyophilized powder is stable at 2-8°C, and the solution state is easily degraded (needs to be kept away from light and at low temperature).

- **pH sensitivity**: The best solubility is in an acidic environment (pH 4-5), and it is easy to precipitate under alkaline conditions.

#### **2. Color and dosage form**

- **API**: Mostly white to off-white crystalline powder (colorless when purity>98%), the salt form affects the subtle color (such as acetate is milky white, pamoate salt is light yellow).

- **Formulation type**:

- **Immediate release dosage form**: lyophilized powder for injection (transparent to slightly opalescent solution).

- **Sustained release microspheres**: PLGA carrier microspheres (diameter 20-100μm, white particles, suspended in a transparent solvent).

- **Implants** (such as Goserelin): milky white cylindrical solid.

#### **3. Solubility and incompatibility**

- **Triptorelin**: Soluble in water (1 mg/mL) and dilute acetic acid, insoluble in ethanol and chloroform. Chelation may occur with syringes containing metal ions (such as aluminum), so compatibility should be avoided.

- **Antagonist Degarelix**: Due to its strong hydrophobicity, it requires a special solvent (mannitol/glacial acetic acid system) for solubilization.

### **3. Clinical application and comparison of advantages and disadvantages**

#### **1. Indications**

- **Tumor field**:

- Prostate cancer (Triptorelin combined with radiotherapy can improve survival rate).

- Breast cancer (premenopausal HR+ patients).

- **Gynecological diseases**: Endometriosis, uterine fibroids.

- **Pediatrics**: Central precocious puberty (CPP).

- **Reproductive medicine**: IVF cycle regulation (antagonist regimen reduces the risk of OHSS).

#### **2. Pharmacokinetic comparison**

| Parameters | Triptorelin (sustained release) | Degarelix (long-acting) |

|---------------|-----------------------|------------------|

| Time to peak (Tmax) | 2-4 weeks (sustained release) | 2 hours |

| Half-life | 7-12 hours (prototype) | 47 days |

| Elimination pathway | Kidney (60%) | Hepatobiliary system |

#### **3. Side effect management**

- **Agonist**: hot flashes (80% of patients), decreased bone density (need to be combined with bisphosphonates).

- **Antagonist**: injection site reactions (about 40% for Degarelix), prolonged QT interval (ECG monitoring required).

### **4. Future development direction**

1. **New delivery system**: nanocrystal technology (extends half-life to 6 months), transdermal patch (improves compliance).

2. **Bifunctional molecules**: GnRH-chemotherapeutic drug conjugates (targeted treatment of ovarian cancer).

3. **Oral formulation development**: Cyclic peptide modification improves intestinal mucosal permeability.

#### **Conclusion**

GnRH analogs have demonstrated irreplaceable value in the field of tumors and reproduction by precisely regulating the gonadal axis. The differentiated properties of agonists and antagonists provide flexible choices for clinical practice, and a deep understanding of their physicochemical properties is the basis for optimizing formulation processes and rational drug use. In the future, with breakthroughs in molecular design and delivery technology, this type of drug is expected to achieve further leaps in efficacy and safety.